Adjuvant chemotherapy with bevacizumab (i.p.) can prolong survival time of patients with advanced ovarian cancer after cytoreduction
Abstract:
Objective To assess whether adjuvant chemotherapy with bevacizumab intraperitoneal (i.p.) is better than adjuvant chemotherapy with bevacizumab intravenous (i.v.) or adjuvant chemotherapy only for patients with advanced ovarian cancer after cytoreduction. Selected patients with advanced ovarian cancer after cytoreduction were divided into three groups depend on their will: adjuvant chemotherapy only; adjuvant chemotherapy combined with bevacizumab intravenous (i.v.); adjuvant chemotherapy combined with bevacizumab intraperitoneal (i.p.). Patients in three groups were given 4-6 cycles of treatment and followed up for 3 years. posttreatment outcome, longterm survival and side effects were prospectively recorded and analyzed. Disease control rate (DCR) of three groups are 73.3%, 90.0%, 93.3% respectively (P Remission rate (RR) and DCR of patients with bevacizumab intraperitoneal (i.p.) are better than that of patients with bevacizumab intravenous (i.v.) (P